Stella Pharma Corporation
Notification of Partial Revision Approval to the Marketing Authorization for Stevoronin® Intravenous Infusion Bag 9000mg/300mL for BNCT Indicated for Recurrent Meningioma
The BNCT pharmaceutical Stevoronin® Intravenous Infusion Bag 9000mg/300mL, indicated for recurrent meningioma, has received partial revision approval to its marketing authorization. This is the first approval in Japan for an indication targeting recurrent meningioma. The company promotes indication expansion as a core growth strategy. National health insurance coverage is scheduled for March 1, 2027.
Key Figures
- Indication expansion approval for recurrent meningioma (new indication)
- Planned start of insurance coverage: 2027-03-01
- Medium- to long-term growth expectations from expanded BNCT treatment indications
AI要約
Summary of Approval
Today, we obtained partial revision approval to the marketing authorization for the BNCT pharmaceutical Stevoronin® Intravenous Infusion Bag 9000mg/300mL to include "recurrent meningioma" in its indications or efficacy. This approval represents an expansion of the indication to recurrent meningioma and is the first such case in Japan.
Strategy and Outlook
The company is advancing its BNCT business based on three pillars: "indication expansion," "expansion of treatment facilities," and "overseas expansion." This approval is an important result for indication expansion and is expected to broaden the range of treatable patients. The company will proceed with related procedures aiming for insurance coverage on March 1, 2027, and after approval, coordination between regulatory measures and insurance through evaluation-based medical care is anticipated.
Stella Pharma Corporation
Company overview · Stock price · Financial data · All IR